Compare · FEMY vs SYK
FEMY vs SYK
Side-by-side comparison of Femasys Inc. (FEMY) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FEMY and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $115.59B, about 355.1x FEMY ($325.5M).
- Over the past year, FEMY is down 66.3% and SYK is down 21.1% - SYK leads by 45.3 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 2 for FEMY).
- SYK has more recent analyst coverage (25 ratings vs 3 for FEMY).
- Company
- Femasys Inc.
- Stryker Corporation
- Price
- $5.37+1661.23%
- $301.60-1.32%
- Market cap
- $325.5M
- $115.59B
- 1M return
- -40.01%
- +2.47%
- 1Y return
- -66.33%
- -21.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 8
- Recent ratings
- 3
- 25
Femasys Inc.
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest FEMY
- Femasys Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Femasys Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Femasys Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
- SEC Form 10-Q filed by Femasys Inc.
- Femasys Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
- Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
- SEC Form DEF 14A filed by Femasys Inc.
- SEC Form DEFA14A filed by Femasys Inc.
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation